LAVAL, QC, Dec. 10 /CNW/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today
announced that James R. Howard-Tripp, President and Chief Executive Officer of
the Company, will participate in the "Deliver Us From Pain" panel discussion
at the RBC Capital Markets 2007 Healthcare Conference on Wednesday,
December 12, 2007 at 11:00 a.m. ET at the Westin Times Square Hotel in New
Interested parties may access the live webcast of this presentation by
visiting the "Events" section of the homepage of the Company's website at
www.labopharm.com. Please connect at least 15 minutes prior to the
presentation to ensure adequate time for any software download that may be
required to join the webcast. An audio archive of the presentation will be
available for 30 days.
About Labopharm Inc.
Labopharm is an emerging leader in optimizing the performance of existing
small molecule drugs using its proprietary controlled-release technologies.
The Company's lead product, a unique once-daily formulation of tramadol, is
being commercially launched in key markets globally. The Company has a robust
pipeline of follow-on products in both pre-clinical and clinical development.
Labopharm's vision is to become a fully integrated, international, specialty
pharmaceutical company with the capability to internally develop and
commercialize its own products. For more information, please visit
This press release contains forward-looking statements, which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual events could differ
materially from those projected herein and depend on a number of factors,
including the uncertainties related to the regulatory process and the
commercialization of the Company's products thereafter, if they are approved.
Investors should consult the Company's ongoing quarterly filings and annual
reports for additional information on risks and uncertainties relating to
these forward-looking statements. The reader is cautioned not to rely on these
forward-looking statements. The Company disclaims any obligation to update
these forward-looking statements.
For further information:
For further information: At Labopharm: Mark A. D'Souza, Chief Financial
Officer, Tel: (450) 686-0207; At The Equicom Group: Jason Hogan, Media and
Investor Relations, Tel: (416) 815-0700, firstname.lastname@example.org; French: Eric
Bouchard, Tel: (514) 844-7997, email@example.com